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Abstract: Establishing a hemoglobin-based oxygen carrier (HBOC) has potential to improve transfusion medicine and 
provide a novel intervention to minimize tissue damage during hypoxic or ischemic insults. However, in vitro studies 
suggest that HBOCs have toxic effects on endothelial cell barrier function. The purpose of this study was to determine if 
the HBOC polymerized bovine hemoglobin (PBvHb) alters pulmonary endothelial barrier function in rats during 
normoxia or hypoxia. Conscious male Sprague-Dawley rats were treated with lactated Ringer’s (LR) or PBvHb (3 ml of 
1.3 mg PBvHb/ml in lactated Ringer’s) and exposed to 4hr of normoxia (FiO2=21%) or hypoxia (FiO2=10%). Evans blue 
dye (EBD) extravasation (estimate of pulmonary vascular leak), pulmonary artery (Pa) pressure, inflammatory mediators, 
vascular endothelial growth factor (VEGF), fms-like tyrosine kinase-1 (sFlt-1), and hypoxia inducible factor-1 (HIF-1 ) 
were measured in the lung and/or plasma. As expected with hypoxia, Pa pressure increased (p<0.05). PBvHb also resulted 
in a significant increase in Pa pressure independent of hypoxia. While a significant main effect of PBvHb on EBD 
extravasation was observed, no differences in inflammatory cytokines or pulmonary white blood cells existed among 
groups. No pulmonary edema was present upon assessment of wet:dry lung weights or histological examination. Hypoxia 
did not influence plasma VEGF, but resulted in a small but significant increase in sFlt-1. Irrespective of hypoxia, PBvHb 
was associated with increased unbound VEGF and its soluble receptor sFlt-1. However, no differences in lung VEGF or 
HIF-1  were observed. We conclude that in this model, acute administration of PBvHb does not have severe overall 
effects on pulmonary endothelial barrier function or inflammation.  
Keywords: Hypoxia, hemoglobin, pulmonary edema, inflammation. 
INTRODUCTION 
In the advancing field of transfusion medicine, the 
potential role of artificial blood and oxygen carriers is still 
unrealized. With the establishment of universal hemoglobin 
based oxygen carriers (HBOC), many obstacles involved 
with allogenic blood transfusions, including disease 
transmission, limited blood supply, short shelf life, and 
donor-recipient complications, could be avoided. Not only 
could use of artificial oxygen carriers reform transfusion 
therapy, it could improve tissue function in individuals 
suffering from various maladies affecting oxygen delivery 
such as vascular disease resulting in cardiac or cerebral 
ischemia [1-4]. Additionally, artificial oxygen carriers could 
provide a novel intervention to prevent tissue damage during 
extreme environmental exposure including hypobaric 
hypoxia. Thus, it is of clinical importance that a safe and 
effective blood substitute be developed.  
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Negative secondary effects that have been associated 
with HBOCs used in clinical settings include increased blood 
pressure and decreased cardiac output, likely from nitric 
oxide (NO) scavenging [5], and toxic effects on endothelial 
barrier function that may stem from oxidation-reduction 
reactions [6-9]. These negative secondary effects have, 
unfortunately, essentially brought human research into the 
safe and effective use of HBOCs to a standstill. However, 
previous research from our laboratory suggests that HBOCs 
can indeed increase oxygen content [10] in both normoxic 
and hypoxic conscious rat models. Importantly, we have 
recently shown that the negative hemodynamic effects [11] 
(hypertension, decreased cardiac output) associated with 
HBOC administration can be moderated or even overcome 
by concurrent use of phosphodiesterase-5 inhibitors or via 
nitrosylation of the hemoglobin [11,12]. Therefore, we 
believe that our conscious rat model employing normoxia 
and hypoxia may represent a viable model for studying the 
utility of HBOC administration in a variety of clinically 
relevant conditions associated with inadequate oxygen 
supply/delivery, unless the secondary toxic effects on 
endothelial barrier function remain problematic.  
52    The Open Physiology Journal, 2010, Volume 3 Jacobs et al. 
As mentioned previously, it is thought that secondary 
toxic effects of HBOCs on endothelial barrier function may 
stem from oxidation-reduction reactions [6-9]. Specifically, 
the autoxidation of oxyhemoglobin (Fe
2+
) leads to 
ferrihemoglobin (Fe
3+
) and a superoxide anion, which 
dismutates into hydrogen peroxide. It has been suggested 
that the reactive oxygen species formed during the 
autoxidation of HBOC can lead to activation of transcription 
factors NF- B [9], hypoxia inducible factor-1  (HIF-1 ) 
[13], stress fiber formation [7], and induction of apoptotic 
cell death [8], all of which can subsequently alter 
endothelium barrier function properties. Investigations of the 
effects of HBOC on the vascular endothelium have primarily 
been conducted in cell culture models in which conditions 
are tightly controlled. For example, previous investigations 
have the specific endothelial cell type (i.e., aorta, pulmonary, 
etc.), molar concentrations of Fe
2+
 and Fe
3+
, time of 
incubation, and additional stressors such as hypoxia or 
hydrogen peroxide rigorously defined [7-9,13]. In addition, 
HBOC that are known to readily auto-oxidize [14] are often 
used. However, in vitro studies of HBOC-induced effects 
cannot take into account the extra- and intracellular enzymes 
that are produced by endogenous antioxidant defense 
systems (glutathione, superoxide dismutase, etc.) and/or 
other factors in the blood and tissue, which may attenuate or 
exacerbate the effects observed in cultured cells. Further, 
many investigations of HBOC physiological effects have 
employed hemorrhagic, hypovolemic and exchange-
transfusion models [15-17]. To our knowledge, no 
investigation to date has focused on pulmonary vascular 
endothelial barrier function after HBOC-infusion in a 
euvolemic animal model during both normoxia and hypoxia. 
Our primary goal for this study was to examine the effect 
of polymerized bovine hemoglobin (PBvHb) administration, 
the HBOC employed in our previous investigations of 
HBOCs and hemodynamics [10-12], on the pulmonary 
vasculature of conscious euvolemic animals, in both ambient 
and hypoxic environments. We chose to investigate PBvHb 
effects in hypoxic conditions as it is well-established that 
hypoxia imposes an increase in pulmonary artery pressure 
that can, in turn impose a stress capable of increasing 
vascular permeability. Therefore, we were interested in not 
only observing the effects of PBvHb on the pulmonary 
vascular barrier in normoxic, euvolemic conditions, but also 
in a setting in which pulmonary vascular barrier function is 
already at risk. Based on previously published findings [6-
9,18,19], we hypothesized that PBvHb infusion would 
induce an inflammatory response and increase vascular 
endothelial growth factor (VEGF), a known permeability 
factor. Therefore, studies were designed to measure 
pulmonary vascular leak via extravasation of Evans Blue dye 
(EBD), plasma and lung inflammatory markers, and VEGF 
concentrations. Secondarily, the experiments were designed 
to determine the PBvHb effect on the upstream transcription 
factor of VEGF, HIF-1 , and, finally, to determine if 
changes in circulating VEGF are reflections of changes in 
the soluble VEGF receptor, fms-like tyrosine kinase-1 (sFlt-1). 
MATERIALS AND METHODOLOGY 
Ethical Approval 
All experimental protocols were reviewed and approved 
by the Institutional Animal Care and Use Committees at 
Colorado State University and/or University of Colorado 
Denver Health Sciences Center. Protocols were consistent 
with the Public Health Service Policy on Humane Care and 
Use of Laboratory Animals. 
Animals  
Male Sprague-Dawley rats (280-350g and 10-12 weeks 
of age) were obtained from Charles River (Wilmington, MA) 
and housed at either Colorado State University Laboratory 
Animal Research facility or the University of Colorado 
Denver Health Sciences Center for Laboratory Animal Care. 
All animals were allowed to acclimate to ambient conditions 
for seven days prior to any experimentation. Animals were 
allowed ad libitum access to food and water and kept on a 12 
hr day-night cycle. All experimental protocols were 
reviewed and approved by the Institutional Animal Care and 
Use Committees at Colorado State University and/or 
University of Colorado Denver Health Sciences Center. 
Experimental Design 
Rats were assigned to one of four groups: (1) normoxic 
conditions (FiO2 =21% O2) treated with lactated Ringer’s 
solution (Henery Schein, Melville NY) (NX-LR); (2) 
normoxic treated with polymerized bovine hemoglobin 
(Biopure™, Cambridge, MA) (NX-PBvHb); (3) hypoxic 
conditions (via exposure to hypoxic gas or hypobaric 
hypoxic equivalent of FiO2=10%) treated with lactated 
Ringer’s solution (HX-LR);or (4) hypoxic treated with 
polymerized bovine hemoglobin infused (HX-PBvHb). Two 
sets of experiments (n=6-10/group for each set of 
experiments) were carried out due to inability to utilize 
tissues from the rats assessed for vascular leak, for 
evaluation of the other dependent variables. The first 
experiments examined the effect of acute PBvHb treatment 
on pulmonary vascular leak and pulmonary artery pressure in 
rats exposed to either normoxia or hypoxia for four hours. 
This duration of hypoxia was based on previous experiments 
identifying clearance of PBvHb in our rat model [10]. The 
second study focused on examining the effects of PBvHb 
infusion on inflammation and circulating inflammatory 
mediators and on permeability factors including vascular 
endothelial growth factor (VEGF) and fms-like tyrosine 
kinase-1 (sFlt-1), known to induce pulmonary vascular leak 
[17-19]. 
Effects of PBvHB on Pulmonary Vascular Leak and 
Pulmonary Artery Pressure 
Instrumentation 
As previously described [10-12], indwelling catheters 
were placed into the jugular vein and pulmonary artery 48 h 
prior to any treatments. Briefly, rats were anesthetized with a 
mixture of ketamine: xylazine (75 mg/kg: 6 mg/kg I.P.) and 
under aseptic conditions a PV-1 (0.28 mm ID, BD 
Diagnostics, Franklin Lakes, NJ) catheter was inserted into 
the right ventricle via the right jugular vein and guided into 
the main pulmonary artery. Pressure tracings confirmed 
placement in the pulmonary artery. Next, a PE-50 (0.58 mm 
ID, BD Diagnostics) catheter was placed in the superior vena 
cava via the right jugular vein for treatment infusions. 
Catheters were flushed with heparinized saline, tied off, 
tunneled subcutaneously to the dorsal neck region, and 
exteriorized at the back of the neck. Animals were allowed at 
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least 48 h to recover prior to any treatments. Animals were 
monitored for signs of infection, diarrhea, or distress and 
were excluded from the study if any such signs were 
apparent (n=1 excluded due to apparent infection).  
Treatments and Pulmonary Artery Pressures 
Rats were placed in custom designed small, rectangular, 
Plexiglas chambers with a portal through which catheters 
could be passed. Catheters were flushed with heparinized 
saline and then connected to fluid filled pressure transducers. 
Animals were exposed to normoxic and hypoxic conditions 
by flushing the chamber with appropriate gases (room air or 
10% oxygen with balance nitrogen). Once breathing hypoxic 
gas, hypoxic animals were not re-exposed to room air. 
Baseline pulmonary artery pressures of normoxic and 
hypoxic animals were collected prior to lactated Ringer’s or 
PBvHb infusion. Animals then underwent a 30 min (1ml/10 
min) venous infusion of either lactated Ringer’s or PBvHb (3 
ml of 1.3 mg PBvHb/ml in lactated Ringer’s). Immediately 
after the infusion, the groups were split, with half remaining 
in room air and half being subjected to hypoxia. Throughout 
exposure to hypoxia, rats were monitored for any signs of 
distress but were otherwise left undisturbed. Four hours after 
infusion and exposure to hypoxia or normoxia, pulmonary 
artery pressures were measured.  
Pulmonary Vascular Protein Extravasation 
As previously described, pulmonary vascular leak was 
assessed by lung protein extravasation determined by the 
Evans blue dye (EBD) method [20]. Briefly, EBD (20 
mg/kg) was injected via the venous catheter following 
lactated Ringer’s or PBvHb treatments and exposure to 
hypoxia or normoxia, but 15 minutes prior to euthanasia with 
an overdose of sodium pentobarbital (100 mg/kg) via the 
jugular catheter. Animals were then transcardially perfused 
with phosphate buffered saline. Each animal’s left caudal 
lobe was removed. After weighing, EBD was extracted from 
by formamide (100%) incubation (18 h, 37°C). The other 
half of the lung was immediately weighed, oven dried (65°C, 
48 h), and weighed again. Wet weight:dry weight ratio in the 
left lung was used to estimate the dry weight of the other half 
of the lung. The extracted dye was quantified in a spectro- 
photometer by measuring the absorbance at 600 nm against 
standards of EBD dissolved in formamide. EBD extravasation 
is expressed as nanograms of EBD per milligram of dried 
tissue. 
Effects of PBvHB on Inflammation, VEGF, and sFlt-1 
Immediately following venous infusion of either lactated 
Ringer’s or PBvHb (3 ml, 1.3 mg PBvHb/ml, 1.3 g PBvHb 
/kg body weight), the groups were split with half remaining 
in room air and half being subjected to hypoxia. Throughout 
exposure to hypoxia, rats were monitored for any signs of 
distress but were otherwise left undisturbed and were not re-
exposed to room air. Four hours following infusion and 
exposure to hypoxic (or normoxic) conditions, animals were 
anesthetized with a mixture of ketamine: Rompon (xylazine) 
(75 mg/kg: 6 mg/kg I.P.) until a surgical plane of anesthesia 
was reached. Blood was withdrawn via cardiac puncture and 
collected into EDTA Vacutainer tubes (BD Diagnostics, 
Franklin Lakes, NJ) and placed on ice until centrifuged at 
4
o
C for 15 minutes at 2800 rpm. Plasma was withdrawn and 
stored at -80
o
C until analyzed. A thoracotomy was 
performed, the left main bronchus ligated, and the left lung 
was removed and immediately frozen in liquid nitrogen. The 
right lung was perfused via the trachea with 10% formalin 
for histological analyses. 
Histology 
Lungs from 3 rats per treatment group were fixed with 
10% buffered formalin by airway inflation at constant 
pressure (~25 cm of H20 pressure), paraffin embedded and 
sectioned to 4 m and stained with hematoxylin and eosin. 
The slides were examined in a blinded fashion for 
neutrophils / macrophages and/or red blood cells in the 
alveolar spaces, thickened alveolar septa, hemorrhage or 
blebs, and interstitial pneumonia. 
Cytokine Microarray Analyses 
Plasma samples were analyzed for inflammatory markers 
using the Meso Scale Discovery Sector Imager 6000 (Meso 
Scale Discovery, Gaithersburg, MD). The Meso Scale 
Imager uses electrochemiluminescence to quantify serum 
protein levels. Interleukins (IL)- 1,4,5, and 13; TNF , 
interferon-  (IFN- ); and growth related oncogene (GRO-kc) 
were determined from a commercially available Meso Scale 
rat inflammatory marker plate following manufacturer’s 
instructions. Samples were run in triplicate and quantified 
against standards provided by the manufacturer.  
Plasma VEGF and sFlt-1 Analyses 
Concentrations for vascular endothelial growth factor 
(VEGF) and the VEGF receptor fms-like tyrosine kinase-1 
(sFlt-1) were analyzed from plasma samples by commercially 
available ELISA kits (R&D Systems, Minneapolis, MN; 
catalog # DY564 and MVR100, respectively). The ELISA 
kit specific for VEGF detected only free VEGF, whereas the 
ELISA kit for sFlt-1 detected total sFlt-1, bound and 
unbound to VEGF.  
Lung HIF and VEGF Analyses: 
HIF1-  DNA Binding 
Nuclear extracts from lung tissue were prepared using the 
Panomics nuclear extraction kit following manufacturer’s 
instructions (Panomics, Fremont, CA). Briefly, frozen tissues 
were homogenized by mortar and pestle, and lysis buffers 
provided by Panomics were used to separate cytosolic and 
nuclear fractions. HIF1-  DNA binding activity in nuclear 
extracts was detected using the commercially available 
enzyme-linked immunoassay (ELISA) kit (Panomics). In 
this assay HIF1-  binds to oligodeoxynucleotides with a HIF 
specific binding site and this binding is detectable at a 
wavelength of 450 nm. Samples were analyzed in 96 well 
plates on a spectrophotometric plate reader (Molecular 
Devices, Sunnyvale, CA).  
Western Blot VEGF Analyses 
The cytosolic fraction remaining from the Panomics lung 
tissue nuclear extraction was used to identify VEGF via 
standard immunoblotting techniques. Protein concentrations 
were determined with a bicinchonic acid protein assay 
(Pierce Biotechnology, Rockford, IL). Samples were stored 
at -80
o
C until analyzed and 35 g of protein was separated 
by standard SDS-polyacrylamide gel electrophoresis using 4-
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15% precast gradient gels (Bio-Rad Laboratories, Hercules, 
CA) followed by transfer to pure nitrocellulose membranes. 
Following transfer, blots were blocked overnight at 4
o
C with 
5% bovine serum albumin in Tris buffered saline with 0.1% 
Tween 20 followed by room temperature incubations in 
primary antibodies for VEGF (VEGF A-20 – rabbit 
polyclonal IgG, sc-152; Santa Cruz Biotechnology, Santa 
Cruz, CA) at a dilution of 1:1000 for 90 min and secondary 
antibodies conjugated to horseradish peroxidase (HRP) 
(stabilized goat anti-rabbit HRP-conjugated, #1858415; 
Pierce Biotechnology) at a dilution of 1:5000 for 60 min. To 
account for any differences in total protein loading, -actin 
was detected by incubation in primary antibodies against -
actin conjugated to HRP (Actin C-2 HRP, sc-8432; Santa 
Cruz Biotechnology) at a dilution of 1:1000 for 60 min. 
Bands were detected via chemiluminescence (West Dura, 
Pierce Biotechnology) with subsequent imaging (UVP 
BioSpectrum, Upland, CA) and densitometric analyses (UVP 
Visionworks). Results were normalized to -actin and 
expressed relative to control (NX-LR) values. 
Statistical Analyses 
Significance level was established a priori at p < 0.05 
with 95% confidence interval. All data were analyzed with 
SPSS 17.0 (SPSS Inc., Chicago, IL) using a general linear 
model analysis of variance and expressed as means ± SEM 
unless otherwise specified. When appropriate, a Tukey HSD 
was employed post hoc to compare between treatment 
means. Data from the plasma concentrations for GRO-kc, 
IL-5, VEGF, sFlt-1 and from wet weight-to-dry weight ratios 
were normalized by a log transformation. Data sets (IFN- , 
IL-1 , IL-4, IL-13, and TNF ) that did not satisfy normal 
distribution criteria and were analyzed using a non-
parametric analysis of variance (Kruskal-Wallis Test).  
RESULTS 
Pulmonary Effects  
Pulmonary Artery Pressure 
As expected, acute hypoxia exposure increased pulmonary 
artery pressure. Independent of the effects of hypoxia, 
PBvHb treatment also resulted in a small but significant 
increase in pulmonary artery pressure (Fig. 1, inset), yet the 
effects of hypoxia and PBvHb were not additive (Fig. 1).  
Evans Blue Dye Protein Extravasation 
Compared to normoxia, EBD extravasation was 
unchanged after 4 hr of acute hypoxia (main effects data not 
shown). However, compared to lactated Ringer (LR) treated 
animals, EBD extravasation was increased in PBvHb treated 
animals (Fig. 2, inset). Lung wet weight:dry weight ratios, 
however, did not differ between LR and PBvHb groups (data 
not shown, p = 0.84). When comparing EBD extravasation 
across all groups, no significant differences were observed 
(Fig. 2). Pearson’s correlation revealed that there was no 
relationship between pulmonary artery pressure and EBD 
extravasation (data not shown).  
Inflammation, VEGF, and sFlt-1 
Plasma Inflammatory Markers 
PBvHb did not affect inflammatory markers, GR0-kc, 
IFN- , IL-1 , 4, 5, or TNF-  during normoxia or hypoxia 
(Table 1). There was no histological evidence of alveolar 
 
Fig. (1). Pulmonary artery (Pa) pressures across all experimental groups (mean±SEM). Inset: PBvHb treatment effect on pulmonary artery 
pressure. LR=lactated Ringer’s, PBvHb=polymerized bovine cell free hemoglobin, NX=normoxia, HX=hypoxia; * significantly greater than 
LR (p < 0.05); † significantly greater than NX-LR (p < 0.001); ‡ significantly greater than NX- PBvHb (p < 0.05); (n=6-9/group). 
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WBC, thickened septa, hemorrhage or blebs and interstitial 
pneumonia. Therefore, for quantification purposes, summa- 
tions of alveolar neutrophils and macrophages were used for 
comparison between groups. Histological analyses showed 
no increases in lung macrophages or neutrophils in PBvHb 
infused animals, suggesting no local inflammatory response 
to PBvHb in the lung (Fig. 3).  
Plasma VEGF and sFlt-1 
VEGF, a protein known to induce pulmonary vascular 
permeability, was determined in the plasma of each animal. 
Plasma VEGF concentration was significantly increased in 
PBvHb treated animals compared to untreated cohorts (Fig. 
4, inset). The form of plasma VEGF measured was that not 
bound to its inhibitory soluble receptor, fms-like tyrosine 
kinase-1 (sFlt-1). Therefore, the concentration of sFlt-1 was 
also determined. We observed greater (p<0.05) plasma sFlt-1 
concentrations in PBvHb infused animals compared to LR 
infused animals (Fig. 4, inset). However, a Pearson correlation 
analyses showed no relationship between VEGF and sFlt-1 
concentrations (data not shown).  
Lung HIF-1  and VEGF 
To investigate whether the lung contributed to increased 
plasma VEGF concentrations, nuclear and cytosolic protein 
in the lung was analyzed for HIF-1  and VEGF, respectively. 
There was no effect of hypoxia or PBvHb on lung or VEGF 
(Fig. 5) HIF-1  DNA binding (Fig. 6). 
DISCUSSION 
Principle Findings 
The goal of this study was to determine if infusion of 
PBvHb, in conscious, euvolemic animals, altered pulmonary 
vascular endothelial barrier function four hours post infusion 
in normoxic and hypoxic environments. Hypoxic models 
were chosen as a means of imposing a clinically and 
environmentally relevant stress for which artificial oxygen 
 
Fig. (2). Pulmonary vascular leak as assessed by Evan’s blue dye (EBD) extravasation (mean±SEM). Inset: PBvHb treatment effect on 
pulmonary vascular leak. LR=lactated Ringer’s, PBvHb=polymerized bovine cell free hemoglobin, NX=normoxia, HX=hypoxia; * 
significantly greater than LR (p < 0.05); (n=6-9/group) 
 
Table 1. Plasma inflammatory cytokines (pg/ml) 4 hours following treatment 
 IFN-  IL-1  IL-4 IL-5* IL-13 GRO-kc* TNF  
NX-LR  
(n=6) 
ND 79.9±23.8 0.1±0.1 1.1±0.3 10.6±9.1† 2.5±0.2 2.9±2.7 
NX-PBvHb 
(n=6) 
0.7±0.4 85.1±28.3 0.07±0.07 1.2±0.3 ND 2.7±0.3 17.3±13.5 
HX-LR  
(n=6) 
ND 41.7±25.2 0.05±0.05 0.3±0.3 ND 2.2±0.2 ND 
HX-PBvHb 
(n=5) 
ND 141.6±85.6 0.04±0.03 1.4±0.3 ND 2.7±0.3 12.1±9.6 
*Indicates data were log transformed to meet the assumptions of equal variance prior to analysis. † indicates different from all other groups for that cytokine. ND = not detected. 
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carriers could provide an effective intervention to prevent 
tissue damage and improve oxygen delivery. The data 
revealed that although PBvHb elicited a small increase in 
EBD extravasation, no frank pulmonary edema was evident 
and no lung or systemic inflammation was detectable in any 
group. An increase in plasma VEGF concentration, 
accompanied by an increase in soluble inhibitory receptor 
sFlt-1, was observed with PBvHb treatment during normoxia 
and hypoxia.  
PBvHb and Pulmonary Vascular Leak 
The novel data presented in the current study are 
contradictory to in vitro reports of cell free hemoglobin 
impairing pulmonary endothelial barrier function. 
Fig. (3). Inflammatory response to PBvHb. Representative images from hematoxylin and eosin staining in paraffin embedded lung tissue. 
Arrows indicate areas with observe WBC infiltration. Inset: Quantification of intra-alveolar white blood cells (WBC) per mm
2
 observed in 
fixed lung sections (mean of 6 fields/section/sample±SEM; n=3/group;). These data were log transformed to meet the assumption of equal 
variance. LR=lactated Ringer’s, PBvHb=polymerized bovine cell free hemoglobin, NX=normoxia, HX=hypoxia.  
 
Fig. (4). Comparison of plasma concentrations of vascular endothelial growth factor (VEGF) and fms-like tyrosine kinase 1 (sFlt-1) across 
experimental groups (mean±SEM). Insets: Effect of treatment with PBvHb on unbound plasma VEGF and total plasma sFlt-1 concentrations. 
These data were log transformed to meet the assumption of equal variance. * significantly greater than LR (p < 0.05). LR=lactated Ringer’s, 
PBvHb=polymerized bovine cell free hemoglobin, NX=normoxia, HX=hypoxia. (n=6-9/group) 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
NX-LR NX-PBvHb HX-LR HX-PBvHb
lo
g
 [
# 
W
B
C
s/
m
m
2 
]
PBvHb effect on VEGF concentration
PBvHb effect on sFlt-1 concentration
1.0
1.5 *
2.0
2.5
3.0 *
LR PBvHb
0.0
0.5
LR PBvHb
1.0
1.5
2.5
3.0
3.5
Unbound VEGF
*
0 5
1.0
1.5
2.0 Total sFlt-1
0.0
.
PBvHb and Pulmonary Leak The Open Physiology Journal, 2010, Volume 3    57 
Endothelial cell culture models have been used previously to 
demonstrate that treatment with cell free or cross linked 
hemoglobin can promote increased permeability and stress 
fiber formation [7], increased apoptotic cell death [13], and 
activation of the transcription factors NF- B [9] and HIF-1  
[13], all of which are known to increase expression of 
permeability factors. It is generally believed that the effects 
of cell free hemoglobin on the vascular endothelium are due, 
at least in part, to reactive oxygen species formation. 
Oxidant formation associated with cell free hemoglobin 
treatment can occur as a result of the spontaneous 
autoxidation process of oxyhemoglobin (HbFe
2+
) to 
ferrihemoglobin (HbFe
3+
). However, it has been suggested 
that PBvHb is not as easily oxidized to met hemoglobin 
compared to other types of cell free hemoglobin such as 
DBBF (bis (3,5 dibromosalicy) fumarate) often used in other 
in vitro studies [13], and thus is less toxic on endothelial 
cells. We previously reported that four hours following 
PBvHb infusion, the metHb concentration in the plasma 
layer increased from 0 to 12% and 2.6% in normoxic and 
hypoxic conditions, respectively [10], suggesting that 
PBvHb-induced less reactive oxygen species formation 
during hypoxia. In the current study, an overall PBvHb 
treatment effect was associated with a small but significant 
increase in EBD extravasation. However, the mechanism(s) 
associated with this observation is unclear. Additionally, 
because we did not observe signs of pulmonary edema, we 
interpret the increase in pulmonary vascular leak that was 
associated with PBvHb infusion as insufficient for 
overwhelming the fluid clearance mechanisms and, 
therefore, incapable of inducing alveolar flooding. No 
significant relationship between pulmonary artery pressure 
and EBD extravasation was found. Taken together, no signs 
of pulmonary edema, inflammation, or inflammatory cell 
infiltration suggested that, in this model, vascular toxicities 
typically attributed to cell free hemoglobin were not 
clinically relevant. Despite what appears to be a clinically 
insignificant finding, it seems prudent to continue to exercise 
caution in monitoring pulmonary health if using cell free 
hemoglobin for clinical applications. 
PBvHb, Inflammation, VEGF, and sFlt-1 
A paucity of published research exists investigating the 
potential effects of cell free hemoglobin on the inflammatory 
response. It was previously reported that cultured endothelial 
cells treated with cell free hemoglobin had greater induction 
of NF- B, an important transcription factor for inflammatory 
cytokines (TNF- , IL-1, 6, and 8) thought to increase 
vascular endothelial permeability [9]. However, we were 
unable to detect any increase in plasma inflammatory 
cytokines or alveolar neutrophils / macrophages 4 h 
following PBvHb infusion. Importantly, these data suggest 
that the small increase in EBD extravasation observed with 
PBvHb was not associated with dectable inflammatory 
mediators.  
Vascular endothelial growth factor is a known 
permeability agent and, during acute hypoxia, has been 
associated with pulmonary vascular permeability [21-25]. 
VEGF protein concentrations are regulated through the 
transcription factor HIF-1 during hypoxia [26]. During 
hypoxia, cytosolic HIF-1  is stabilized by inhibition of 
oxygen dependent enzymatic hydroxylation of proline 
residues [3,4,7]. HIF-1  subsequently translocates to the 
nucleus where it binds the constitutively expressed -subunit 
 
Fig. (5). Western blot analyses of lung VEGF (mean±SEM). (A) 
Representative images from western blot analyses; (B) Average 
densitometric analysis of VEGF western blots (n=6-9/group); 
normalized to -actin and expressed as percent of mean NX-LR. 
LR=lactated Ringer’s, PBvHb=polymerized bovine cell free 
hemoglobin, NX=normoxia, HX=hypoxia. 
 
Fig. (6). DNA binding analyses of lung HIF1-  (mean optical 
density±SEM). HIF1-  DNA binding activity in nuclear extracts 
was detected using the commercially available enzyme-linked 
immunoassay (ELISA) kit (Panomics). HIF1-  binds to 
oligodeoxynucleotides with a HIF specific binding site and this 
binding is detectable spectrophotometrically at a wavelength of 450 
nm. No significant differences (p>0.05) were detectable. 
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(HIF1- ), forming HIF-1. In addition to hypoxia, it has been 
suggested that HIF-1  stabilization can occur can occur via 
reactive oxygen species generation [27]. Recently, Yeh and 
Alayash [13] reported that HIF-1  expression was increased 
in bovine aortic endothelial cells incubated with the 
chemically modified hemoglobin DBBF (bis (3,5 
dibromosalicy) fumarate). Further, their data showed that 
HIF-1  activation corresponded linearly with the decay of 
HbFe
2+
 and accumulation of the ferric form (HbFe
3+
). In the 
current study, four hours after PBvHb infusion, there was no 
difference between groups in either lung nuclear HIF-1  or 
cytosolic VEGF concentration. Though not assessed directly 
in the experiments reported here, previous experiments in 
our laboratory suggest that this may be a reflection of a small 
percentage of PBvHb that decayed to Fe
3+
 by four hours post 
treatment [10]. Indeed, both hypoxia and reactive species 
[28] can increase VEGF and sFlt-1 via activation of HIF-1  
[28,29]. Our finding of greater unbound VEGF in presence 
of greater total (bound and unbound) sFlt-1 with PBvHb 
infusion during hypoxia, suggests that there was an increase 
in circulating VEGF rather than a decrease in VEGF soluble 
receptor binding. 
CONCLUSIONS 
In conclusion, in euvolemic rats exposed to either 
normoxia or hypoxia and treated with PBvHb, a small 
increase in EBD extravasation (an estimate of vascular leak) 
was observed. However, this occurred in the absence of a 
detectable systemic or local inflammatory response and in 
the absence of pulmonary edema. Modest increases in 
plasma VEGF and sFlt-1 concentrations were observed with 
no increase in lung HIF activation or VEGF expression. 
While it is important to consider species differences with 
respect to susceptibility to vascular leak and other factors 
including endogenous antioxidants when evaluating the 
potential usefulness of cell free hemoglobin, the current 
findings suggest that in a euvolemic rodent model under both 
normoxic and hypoxic conditions, there is an absence of an 
acute inflammatory response or lung damage following 
PBvHb treatment.  
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ABBREVIATIONS 
EBD = Evans blue dye 
Fe
2+
 and Fe
3 = 
Ferrous and ferric iron 
FiO2 = Fraction of inspired oxygen 
GRO-kc = Growth related oncogene; CXCL1 
HBOC = Hemoglobin-based oxygen carrier 
HIF-1  = Hypoxia inducible factor-1alpha 
HX-LR = Hypoxic conditions treated with lactated 
Ringer’s solution  
HX-PbvHb = Hypoxic treated with polymerized bovine 
hemoglobin infused 
IFN-  = Interferon-gamma  
IL = Interleukin 
LR = Lactated Ringer’s 
NF- B = Nuclear factor kappa B 
NO = Nitric oxide 
NX-LR = Normoxic conditions treated with lactated 
Ringer’s solution 
NX-PbvHb = Normoxic treated with polymerized bovine 
hemoglobin 
Pa = Pulmonary artery pressure 
PbvHb = Polymerized bovine hemoglobin 
sFlt-1 = Fms-like tyrosine kinase-1 
TNF  = Tumor necrosis factor alpha 
VEGF = Vascular endothelial growth factor 
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